Abcam (#ABC) – proposed AIM cancellation, noting listing on Nasdaq Global Select Market

Abcam (#ABC) – agreement to acquire BioVision, Inc. for $340m

Table of shorted AIM shares - week to 26/03/2021

From the FCA's spreadsheet of short positions required to be disclosed to it, the following shows the shorted AIM shares with positions from 2019, 2020 and thus far in 2021 (by net short position %, those in bold not on the list at the start of 2021) – and if this position has increased (red), reduced (green) or remained unchanged (black) since last week...

Abcam (#ABC) – filing of registration statement re. proposed IPO of American Depositary Shares

Abcam: clever science + an upcoming Nasdaq listing = ?...

I have always been quite impressed by Abcam (ABC), which I described back in April as 'a thematic growth investment - and not for widows, orphans or neophyte investors - with an earnings multiple of around 30 times and a play on where profitability might be in a few years time off clever science discoveries and processes'. In that article I observed that following the lead of a big institutional investor who negotiated buying a slug of the company at 1100p. Since then the stock has returned to the 1300p+ range and quite rightly so...

Table of shorted AIM shares - week to 04/09/2020

From the FCA's spreadsheet of short positions required to be disclosed to it, the following shows the shorted AIM shares with positions from 2019 and thus far in 2020 (by net short position %, those in bold not on the list at the start of 2020) – and if this position has increased (red), reduced (green) or remained unchanged (black) since last week...

Abcam - clever science company raising money at a small premium

Abcam (#ABC) – completion of acquisition of Expedeon AG’s Proteomics & Immunology business

Table of shorted AIM shares - week to 11/10/2019

From the FCA's spreadsheet of short positions required to be disclosed to it, the following shows the shorted AIM shares with positions from 2018 and thus far in 2019 (by net short position %, those in bold not on the list at the start of 2019) – and if this position has increased (red), reduced (green) or remained unchanged (black) since last week...

Abcam – still fascinating, still volatile

Something a little different this morning and that is another quick look at the AIM market-listed Abcam (ABC), which I last wrote about back in March. Back then I concluded about the "pretty fascinating company making, sourcing and selling a range of 'highly validated biological binders and assays to help study the important targets in critical biological pathways'" that:

Abcam – a clever, innovative, fat cat pay company whose shares are down 11% today

I have not written on Abcam (ABC) but given the nature of its last appearance on this website ("Abcam fat cats and useless 1%-er Non Execs") many will think just desserts about today's 11% share price fall (as I write)…

Back Roger Lawson as he takes on the Abcam fat cats and useless 1%-er Non Execs

Roger Lawson of ShareSoc is er…not always right but his latest battle is one where he is bang on the money. Lawson is a shareholder in Abcam (ABC) and thinks the board is taking the piss and need an AGM wake-up call. He is absolutely right.

Abcam (#ABC) – trading “in line”, including H1 constant currency revenue growth of approx. 11%

Abcam (#ABC) – AGM update, “current year has started well”

Zak Mir's Bull Call of the Day No. 1: Abcam: 700p 2014 Price Channel Target

What can be seen on the daily chart of Abcam is the way that since the sharp spike through the 200 day line then lying towards 400p, and now at 553p.